Background: Epidemiologic studies examining associations between carotenoid intakes and risk of breast cancer by estrogen receptor (ER) and progesterone receptor (PR) status are limited. Objective: We investigated these associations in a pooled analysis of 18 cohort studies. Design: Of 1,028,438 participants followed for a maximum followup of 26 y across studies, 33,380 incident invasive breast cancers were identified. Study-specific RRs and 95% CIs were estimated by using Cox proportional hazards regression and then pooled by using a random-effects model. Results: a-Carotene, b-carotene, and lutein/zeaxanthin intakes were inversely associated with the risk of ER-negative (ER2) breast cancer (pooled multivariable RRs of the comparison between the highest and lowest quintiles): a-carotene (0.87; 95% CI: 0.78, 0.97), b-carotene (0.84; 95% CI: 0.77, 0.93), and lutein/zeaxanthin (0.87; 95% CI: 0.79, 0.95). These variables were not inversely associated with the risk of ER-positive (ER+) breast cancer (pooled multivariable RRs for the same comparison): a-carotene (1.04; 95% CI: 0.99, 1.09), b-carotene (1.04; 95% CI: 0.98, 1.10), and lutein/zeaxanthin (1.00; 95% CI: 0.93, 1.07). Although the pooled RRs for quintile 5 for b-cryptoxanthin were not significant, inverse trends were observed for ER2 and ER+ breast cancer (P-trend 0.05). Nonsignificant associations were observed for lycopene intake. The associations were largely not appreciably modified by several breast cancer risk factors. Nonsignificant associations were observed for PR-positive and PR-negative breast cancer. Conclusions: Intakes of a-carotene, b-carotene, and lutein/zeaxanthin were inversely associated with risk of ER2, but not ER+, breast cancer. However, the results need to be interpreted with caution because it is unclear whether the observed association is real or due to other constituents in the same food sources.
INTRODUCTION
Carotenoids are fat-soluble pigments present in red, yellow, orange, and dark-green fruit and vegetables. More than 600 carotenoids occur in nature, with the most commonly studied carotenoids being a-carotene, b-carotene, b-cryptoxanthin, lutein, zeaxanthin, and lycopene because of their abundance in the diet and comparatively high concentrations in plasma (1) . Car-otenoids have been hypothesized to protect against carcinogenesis (2) by inhibiting the ability of reactive oxygen species to induce DNA damage-a crucial step in carcinogenesis and neoplastic transformation (3) (4) (5) . In addition, provitamin A carotenoids (including a-carotene, b-carotene, and b-cryptoxanthin) can be metabolized to retinol, which is important for the control of cellular differentiation and proliferation and immunologic functions (6) . Other specific mechanisms have been identified for some carotenoids. For example, lutein/zeaxanthin might reduce cell proliferation and b-carotene (7), and lycopene might inhibit estrogen receptor-mediated signaling of 17b-estradiol and attenuate its deleterious effect on breast cancer (7) .
Epidemiologic evidence from ;50 case-control studies and 15 cohort studies examining the associations between carotenoid intakes and overall breast cancer risk has been inconsistent (8) .
The mixed results may be due in part to the fact that most epidemiologic studies have viewed breast cancer as a single disease. Indeed, breast cancer defined by hormone receptor status appears to be etiologically and clinically heterogeneous (9) (10) (11) (12) (13) . ER 4 and PR status are commonly used to define breast cancer subtypes, and the majority of early studies focused on only ER status (10) . Because mechanisms independent of steroid hormones might play a more important role in ER2 breast cancer (9-13), we hypothesized that carotenoid intakes might reduce risk of ER2 breast cancer but not ER+ breast cancer, which is mainly influenced by hormones. We tested this hypothesis by examining the associations between intakes of specific carotenoids and risk of ER2 breast cancer in the Pooling Project of Prospective Studies of Diet and Cancer (14) -an international consortium including .1 million women. We conducted secondary analyses by PR status or jointly by ER and PR status because these associations have received little attention to date (15) (16) (17) .
SUBJECTS AND METHODS

Study population
For these analyses, we included 18 prospective cohort studies (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) that met the following inclusion criteria: ascertainment of 25 incident cases of invasive ER2 breast cancer and 25 cases of invasive PR2 breast cancer; publication of at least one diet and cancer analysis; assessment of long-term dietary intake, including intake of the 5 major dietary carotenoids; and evaluation of the validity of the dietary assessment method or a closely related instrument. Each included study was approved by the institutional review boards of the participating institutions.
Ascertainment of breast cancer cases
Incident invasive breast cancer cases were identified in each study through follow-up questionnaires and confirmed with subsequent medical record review (22, 31, 33) , linkage with cancer registries (20, 21, 23, 24, 27, 28, 32, (34) (35) (36) , or both (19, 25, 26, 29, 30) . Mortality registries were also used in some studies to ascertain additional cases (19, 20, 22, 25, 26, 29, 33, 35) . Follow-up rates exceeded 90% for 16 of 18 current studies (14, (37) (38) (39) (40) (41) (42) included in this analysis and is 80% for all studies (37) (38) (39) (40) (41) (42) (43) (44) . We used the receptor status data from each study to define breast cancer subtypes by ER/PR status. We classified the cases with borderline ER/PR status as being positive for that receptor. The overall proportion of missing of ER/PR status was ;27% in this study.
Dietary and nondietary assessment
Each study assessed usual dietary intake by using a selfadministered FFQ and calculated daily consumption of each of the major carotenoids (a-carotene, b-carotene, b-cryptoxanthin, lutein/zeaxanthin, and lycopene; food sources only). Lutein and zeaxanthin were analyzed together because most food-composition databases report only a combined value for them (1, 45, 46) because of laboratory difficulties in separating them. We calculated daily energy-adjusted carotenoid intakes by using the residual method (47) . Total carotenoid intake was calculated by summing the intakes of the 5 specific carotenoids in each study. We also calculated a total carotenoid score. For the score, intake of each of the 5 carotenoids was categorized into quintiles (1 = lowest quintile, 5 = highest quintile) and then the quintile scores for the 5 carotenoids were summed for each participant. The total carotenoid score ranged from 5 to 25 across participants.
Although the food intake estimates from the FFQ used in each study or a closely related instrument were compared with intakes estimated from multiple 24-h recalls or days of diet records, only a few of the calibration studies assessed intakes of specific carotenoids (34, (48) (49) (50) (51) . The correlation coefficients between b-carotene or carotene intakes estimated by the FFQ and comparison method ranged from 0.30 to 0.60 (34) . The correlation coefficients between dietary intake estimated from the FFQ and plasma concentrations for the 5 major carotenoids ranged from 0.21 for lycopene to 0.48 for a-carotene among nonsmokers in the Nurses' Health Study (48) and ranged from 0.28 for lycopene to 0.46 for b-cryptoxanthin in the Melbourne Collaborative Cohort Study (51) .
b-Cryptoxanthin intake is positively correlated with dietary vitamin C intake (correlation coefficients ranged from 0.6 to 0.9 across studies) because both are concentrated in citrus fruit and fruit juices (45, 46) . Correlations comparing vitamin C intake estimates from the FFQs with those from multiple 24-h recalls or diet records might serve as a reasonable surrogate of the validity of b-cryptoxanthin intake. The correlation coefficient between the FFQs used in these studies or closely related instruments and multiple days of dietary records or 24-h recalls ranged from 0.3 to 0.8 for vitamin C intake (18, 20, 35, 53, 54) . Information on nondietary factors was also collected by each study by using self-administered questionnaires at baseline.
Statistical analyses
After applying the study-specific exclusion criteria, we further excluded participants with a history of cancer at baseline (except for nonmelanoma skin cancer) and who reported energy intakes .3 SDs from their study-specific log e -transformed mean energy intake. We analyzed the Netherlands Cohort Study as a casecohort study, because dietary questionnaires were processed for only the cases and a random sample of the total cohort (55) . We analyzed the Nurses' Health Study as 2 different cohorts [1980-1986, Nurses' Health Study (a); 1986-2006, Nurses' Health Study (b)] to take advantage of the more detailed dietary assessment available in 1986. These 2 blocks of person time, obtained from the same participants, are asymptotically uncorrelated according to the underlying theory of survival analysis (56) , given that each person contributed only one outcome event and was then censored (ie, a woman who developed breast cancer in the 1980-1986 period would not be included in the 1986-2000 period).
We used Cox proportional hazards regression (57) to estimate study-specific RRs and 95% CIs. We calculated person-years of follow-up from the date of questionnaire return to the date of diagnosis of incident invasive breast cancer, death, loss to followup (if applicable), or end of follow-up, whichever came first. We modeled age at baseline (in y) and year of questionnaire return as stratification variables to adjust simultaneously for age, calendar time, and time since entry into the study (14) . In the multivariable analyses, we controlled for the following breast cancer risk factors: race-ethnicity, family history of breast cancer, personal history of benign breast disease, education, physical activity, BMI, height, age at menarche, age at first birth, parity, smoking habits, alcohol consumption, total energy intake, use of oral contraceptives, menopausal status at baseline, and postmenopausal hormone use among postmenopausal women. For each measured confounding variable in a study, we created a missing indicator variable for missing data because the proportion of missing data in the Pooling Project is generally low (14) . We either adjusted for the abovementioned covariates directly in the model or we adjusted for confounders by using the propensity score method (58) (59) (60) when the number of cases of the outcome evaluated within a study was ,200.
We pooled the study-specific RRs weighted by the inverse of their variances by using a random-effects model (61, 62) and tested for between-studies heterogeneity using the Q statistic (62, 73) . All statistical analyses were 2-sided with a P value of 0.05 indicating significance. We conducted all analyses by using the SAS software (version 9; SAS Institute Inc).
We conducted separate analyses for each carotenoid by using study-specific quintiles. The study-specific quintile cutoffs were based on the distributions in the subcohort in the case-cohort study and based on the baseline cohort distributions for the remaining studies. To calculate the P value for the test for trend across categories, we used the median value for each intake category and modeled that variable as a continuous term. We tested for nonlinearity in the breast cancer association for each carotenoid by using restricted cubic splines (64, 65) . In these analyses, we combined all studies into one data set, stratified by study, age, and year of questionnaire return and adjusted for the abovementioned confounding variables. We used a likelihood ratio test to compare the model including the linear and cubic spline terms selected by a stepwise regression procedure with the model including only the linear term for the carotenoid of interest. If the assumption of linearity held for the association between intake of a specific carotenoid and breast cancer risk, we further analyzed that carotenoid as a continuous variable.
We evaluated whether the observed association between intake of each carotenoid and breast cancer risk was modified by menopausal status at diagnosis (66) (premenopausal, postmenopausal), family history of breast cancer (yes, no), BMI (in kg/m 2 ; ,25, 25), multivitamin use (yes, no), alcohol consumption (nondrinker, 1 to ,15 g/d, 15 g/d), smoking status (never, past, current), approximate median age at diagnosis (,64 y, 64 y), and follow-up period (,5 y, 5 y) by using a mixed-effects meta-regression model (67) . We used a contrast test (68) to examine whether the associations were differed significantly for subtypes of breast cancer defined by receptor status (ER2 compared with ER+, PR2 compared with PR+, and across the 4 subtypes jointly defined by ER/PR status).
We conducted further analyses to investigate the potential influence of measurement error on the associations between a-carotene, b-carotene, b-cryptoxanthin, and lutein/zeaxanthin intakes and risk of ER2 breast cancer. The method of Hamling et al (69) was used to obtain the expected cell counts of the 2 · 2 tables for the extreme quintile contrast after controlling for confounding, which produced RRs and 95% CIs matching those of the original study-specific multivariate analyses. These 2 · 2 tables were then adjusted for estimates of measurement error in intake by the matrix method of Barron (70) , and the 95% CIs were obtained to account for both the variance of the multivariate RRs obtained in the main study and the estimation of the misclassification probability in the study-specific validation study (71) . Because few studies measured intake of the individual carotenoids in their validation studies, the misclassification matrix for total carotene intake was used as the best estimate of the expected misclassification in a-carotene, b-carotene, and lutein/zeaxanthin intakes; dietary vitamin C intake was used to approximate the measurement error in b-cryptoxanthin intake. When carotene or dietary vitamin C intake was not assessed in the validation study for a study, we used the misclassification matrix from a similar FFQ; when this was not possible, the pooled misclassification matrix from the other validation studies was used. In some studies, the misclassification matrix produced one or more negative cell counts; when this occurred, we adjusted the misclassification matrix by the power transformation closest to but less than 1 (72) . One validation study required an additional adjustment before the power transformation was taken (73) .
RESULTS
During 7-26 y of follow-up of 1,028,438 participants in the 18 prospective cohort studies, 33,380 incident invasive breast cancer cases were identified with 7-26 y of follow-up in these 18 prospective cohort studies. More hormone receptor-positive breast cancer cases than hormone receptor-negative breast cancer cases were identified (19, Large variability in carotenoid intake was observed across studies, with the range in the median intakes of the carotenoids varying from ;3-fold (b-carotene) to 13-fold (b-cryptoxanthin) across studies ( Table 1 ). The Pearson correlation coefficients comparing intakes of the 5 major carotenoids with one another ranged from ;0.2-0.8 across studies, with the highest correlations generally being observed between a-carotene and b-carotene intakes (r . 0.5) and relatively lower correlations generally being observed for intake of other carotenoids (r , 0.3).
Because the age-adjusted results were similar to the multivariable-adjusted results, we present only the multivariable results. Of the 5 carotenoids evaluated, a significant association with risk of overall breast cancer was observed for only b-cryptoxanthin intake, and that association was relatively weak (pooled multivariable RR comparing the highest with lowest quintile = 0.95; 95% CI: 0.92, 0.99; P-trend = 0.01). For the remaining carotenoids, the pooled multivariable RRs comparing the highest with lowest quintile ranged from 0.98 to 1.00 ( Table  2) . For each carotenoid, the test for between-studies heterogeneity for the extreme quintile contrast was not significant (between-studies heterogeneity test, P 0.05 for all; data not shown). We also conducted analyses in which we modeled intake of each carotenoid as a continuous variable, because no nonlinearity was evident in the associations between intakes of each carotenoid and risk of overall breast cancer (test for nonlinearity, P . 0.10). The results were largely not significant (Table 2) .
When we examined ER+ and ER2 breast cancers separately, for a-carotene, b-carotene, and lutein/zeaxanthin intakes, the risk of ER2 breast cancer was 13-16% lower for comparisons of the highest compared with the lowest quintiles, whereas null associations were observed for ER+ breast cancer (Table 2) . Although the pooled RRs for quintile 5 for b-cryptoxanthin were borderline significant, inverse trends were observed for both ER2 and ER+ breast cancer (P-trend 0.05). Total carotenoid intake was inversely associated with the risk of ER2 breast cancer (pooled multivariable RR comparing the highest with lowest quintile: 0.86; 95% CI: 0.78, 0.94) but not with the risk of ER+ breast cancer (pooled multivariable RR for the same comparison: 1.03; 95% CI: 0.99, 1.08). Results were similar for the total carotenoid score derived by summing the quintile scores for each carotenoid (data not shown). Comparison of the highest with the lowest decile showed that the associations for ER2 and ER+ breast cancer were similar in magnitude to those presented in Table 2 for the quintile analyses.
Because the tests for nonlinearity of the associations between intakes of the specific carotenoids and risk of ER2 and ER+ breast cancers were not significant (test for nonlinearity, P . 0.05 for all), we conducted additional analyses in which carotenoid intakes were modeled as continuous variables. The pooled multivariable RRs for the 5 major carotenoids ranged from 0.93 to 1.01 for an increment based on the approximate median difference between the study-specific 90th percentile and 10th percentile in intake ( Table 2 ). As observed in the quintile analyses, there was a weak inverse association for b-carotene and lutein/zeaxanthin intakes with risk of ER2 but not ER+ breast cancer (test for common effects by ER status, P , 0.05). Nonsignificant associations were observed for a-carotene, b-cryptoxanthin, and lycopene intakes for ER2 and ER+ breast cancers. Further analysis restricted to whites yielded similar Cohort size reflects the size after application of study-specific exclusion criteria and further exclusion of participants with energy intakes
.3 SDs of their log e -transformed study-specific mean energy intake and history of cancer diagnosis at baseline (except for nonmelanoma skin cancer); the Netherlands Cohort Study was analyzed as a case-cohort study, and the above exclusions were not applied to its baseline cohort size.
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6 P value for test for differences between ER2 and ER+ subtypes. were essentially unchanged when we further adjusted for dietary folate and vitamin C intakes. Moreover, results on lycopene intake were similar when we restricted our analyses to studies in which consumption of tomato sauce or tomato products (for which the lycopene is more bioavailable) was assessed. None of the carotenoids were significantly associated with the risk of PR+ breast cancer in either the quintile or continuous analyses. Only b-cryptoxanthin (when modeled as a continuous variable) was significantly associated with risk of PR2 breast cancer. There was no significant between studies heterogeneity for these results.
Intakes of each carotenoid were not associated with the risk of ER+ PR+ or ER+ PR2 breast cancer, with the pooled multivariable RRs comparing the highest with the lowest quintile ranging from 0.91 to 1.08 ( Table 3) . b-Carotene intake was modestly inversely associated with risk of ER2 PR2 breast cancer (pooled multivariable RR comparing the highest with the lowest quintile: 0.87; 95% CI: 0.78, 0.96; P-trend = 0.01). A similar inverse association was observed for lutein/zeaxanthin intake with the risk of ER2 PR2 breast cancer (pooled multivariable RR comparing the highest with the lowest quintile: 0.89; 95% CI: 0.81, 0.99; P-trend = 0.16). In general, the strongest inverse associations were observed for risk of ER2 PR+ breast cancer, although the CI for each carotenoid was wide because of the relatively small number of cases (n = 645) compared with the other subtypes.
We conducted further analyses to examine whether the associations with ER2 and ER+ breast cancer differed by several breast cancer risk factors or factors that may interact with carotenoids by acting through the oxidative stress pathway. The associations between carotenoid intakes and risk of ER+ and ER2 breast cancer were generally not significantly modified by menopausal status at diagnosis (Table 4) , alcohol consumption (Table 5) , smoking status (Table 5) , family history of breast cancer (data not shown), BMI (data not shown), or multivitamin use (data not shown). In addition, results generally did not vary by age at diagnosis and follow-up time (data not shown). Because a relatively large number of comparisons were made in the stratified analyses, the results need to be interpreted with caution.
In analyses that corrected for misclassification in carotenoid intake estimates by using carotene or dietary vitamin C intake data in the validation studies to approximate the measurement error for the specific carotenoids, the risk estimates observed were substantially strengthened but less precise. The corrected pooled multivariable RRs (95% CIs) comparing the highest with the lowest quintile of intake in relation to ER2 breast cancer were 0.57 (0.44, 0.73) for a-carotene, 0.70 (0.54, 0.90) for b-carotene, 0.81 (0.67, 0.99) for b-cryptoxanthin, and 0.75 (0.53, 1.07) for lutein/zeaxanthin. No significant between-studies heterogeneity was observed either before or after correction for misclassification in the intake estimates.
DISCUSSION
In general, no significant associations were observed between carotenoid intakes and risk of breast cancer overall and for ER+, PR+, and PR2 breast cancers. However, higher intakes of specific carotenoids were associated with a modest reduction in the risk of ER2 breast cancer. These associations were largely not significantly modified by menopausal status, family history of breast cancer, alcohol consumption, smoking status, BMI, multivitamin use, median age at diagnosis, or follow-up time.
The relation between dietary carotenoid intakes and overall breast cancer risk has been investigated in 15 cohort studies and 50 case-control studies with mixed results (8) . A modest inverse association has been reported by most case-control studies, but most cohort studies have reported null results (8) . Most case-control studies conducted before the mid-1990s reported inverse associations with b-carotene intake and breast cancer risk (8) . However, these studies most likely measured multiple provitamin A carotenoids expressed in b-carotene equivalents rather than b-carotene itself, because comprehensive food-composition databases for individual carotenoids were not available until the mid-1990s (46, 48) . Studies that evaluated intakes of the 5 major carotenoids reported null or weak inverse associations between intakes of each carotenoid and breast cancer risk, although the observed inverse associations have not been specific to a particular carotenoid (8) . We generally observed null associations between intakes of the 5 major carotenoids and risk of overall breast cancer. No consistent results for a single carotenoid measured in plasma (74, 75) or breast adipose tissue (76) have been reported. Taken together, the associations between each of the major carotenoids (assessed either via questionnaire, in blood, or in adipose tissue) and overall breast cancer risk generally have been inconsistent. Treating breast cancer as a single disease might have contributed to the inconsistent results observed across studies because breast cancer subtypes defined by ER and PR status may be etiologically, as well as clinically, heterogeneous (9-13).
To date, relatively few studies examined associations between intakes of the 5 major carotenoids and risk of breast cancer according to ER/PR status, and most of these studies have been limited by a small number of cases for the less common subtypes (15) (16) (17) . A relatively small population-based case-control study conducted in Australia in the early 1990s showed a stronger inverse association of b-carotene intake with risk of ER2 breast cancer than with risk of ER+ breast cancer (15) . Other studies reported only breast cancer subtypes defined by ER and PR status jointly. A population-based case-control study found no associations between intakes of the 5 major carotenoids and risk of any of the breast cancer subtypes defined jointly by ER/PR status (17) . In contrast, the Women's Health Initiative Observational Study reported an ;20% lower risk of ER+ PR+ breast cancer for a-carotene, b-carotene, and lycopene intakes comparing the highest with the lowest quintiles of intake, but null associations for intakes of these carotenoids and risk of ER+ PR2 and ER2 PR2 breast cancers (16) . In our study, weak inverse associations were observed for a-carotene, b-carotene, and lutein/zeaxanthin and risk of ER2 breast cancer. We found null associations between intakes of each of the 5 major carotenoids and risk of ER+, PR+, and PR2 breast cancers. Previous studies examining breast cancer subtypes defined by ER Table 1 as 10th and 90th percentiles. ER, estrogen receptor; ER+, estrogen receptor positive; ER2, estrogen receptor negative; PR, progesterone receptor; PR+, progesterone receptor positive; PR2, progesterone receptor negative.
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Calculated by using a contrast test. and PR status jointly have had limited power to examine ER2 PR+ breast cancers because they have included ,40 cases of ER2 PR+ breast cancer (16, 17) . Our study also showed null associations between intakes of each of the major carotenoids and risk of ER+ and PR+ and ER+ PR2 breast cancers. However, intakes of a-carotene, b-carotene, and lutein/zeaxanthin were associated with a slightly lower risk of ER2 PR2 and ER2 PR+ breast cancers. Differences in clinical, pathological, and molecular features of breast cancer defined by ER and PR status suggest etiologic heterogeneity (9-13). The suggestive inverse associations observed for a-carotene, b-carotene, and lutein/zeaxanthin intakes and risk of ER2 breast cancer in our study support the possibilities that the effect of dietary factors, if any, might be confined to the less hormone-dependent ER2 breast cancer and that carotenoid intakes might not have an important influence on ER+ breast cancer. However, experimental studies have shown that b-carotene and lycopene inhibit the growth of both ER+ and ER2 cell lines (77) .
Our pooled analysis had several strengths. In contrast with small studies with homogeneous populations, the large sample size and wide variation in carotenoid intakes allowed for more powerful analyses of the main effects of each of the major carotenoids with risk of breast cancer subtypes defined by ER/PR status and for evaluation of whether these associations were modified by several breast cancer risk factors. In addition, the prospective cohort design with high follow-up rate minimized the potential for recall or selection bias. We adjusted for multiple established or potential breast cancer risk factors to minimize confounding, and the age-adjusted results were almost identical to the multivariable adjusted results, which suggests that these associations were minimally confounded by these factors.
Our study had several limitations. Measurement error occurred as a result of assessing intake of the specific carotenoids with the use of FFQs. Most studies did not collect information on cooking methods for the specific fruit and vegetables consumed, and how fruit and vegetables are prepared and consumed may influence the bioavailability of carotenoids (1, 46) . However, correlations of plasma concentrations of specific carotenoids with carotenoid intakes assessed by the FFQ and also by 2 wk of weighed diet records were very similar in the Nurses' Health Study and the Nurses' Health Study II (78) . In addition to differences in chronic intakes, plasma concentrations of carotenoids are also influenced by differences in metabolism, including the recently described genetic variation in the b-carotene monoxygenase gene (79) . Therefore, although bioavailability and differences in metabolism do not contribute to errors in measuring intake, they will affect plasma concentrations of carotenoids and probably the RRs were adjusted for the covariates listed in Table 2 . For the analyses of ER+ breast cancer, the number of cases was 6200 in the nondrinker group, 9653 in the >0 to <15 g/d group, and 2289 in the 15 g/d group; 8614 in the never smoking group, 5739 in the past smoking group, and 2470 in the current smoking group. For the analyses of lutein/zeaxanthin intake, the number of ER+ breast cancer cases was 6100 in the nondrinker group and 8518 in the never smoking group; the number of ER+ breast cancer cases in the remaining groups did not change. For the analyses of ER2 breast cancer, the number of cases was 1438 in the nondrinker group, 2310 in the >0 to <15 g/d group, and 454 in the 15 g/d group; 2166 in the never smoking group, 1225 in the past smoking group, and 616 in the current smoking group. For the analyses of lutein/zeaxanthin intake, the number of ER2 breast cancer cases was 1373 in the nondrinker group and 2099 in the never smoking group; the number of ER2 breast cancer cases in the remaining groups did not change. ER, estrogen receptor; ER+, estrogen receptor positive; ER2, estrogen receptor negative. The Black Women's Health Study was excluded from the analyses because information on alcohol consumption was not received from that study.
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The Swedish Mammography Cohort was excluded from the analyses stratified by smoking status because smoking status was not measured at baseline in this study. The Japan Public Health Center-based Study Cohort I was also excluded from the past and current smoking groups because of sparse stratum-specific case numbers. For the analysis of ER2 breast cancer, the Beta-Carotene and Retinol Efficacy Trial was excluded from the never and past smoking groups because of sparse stratum-specific case numbers.
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The Japan Public Health Center-based Study Cohort I was excluded from the .0 to ,15 g/d alcohol group because of sparse stratum-specific case numbers. For the analysis of ER2 breast cancer, the Beta-Carotene and Retinol Efficacy Trial was excluded from the .0 to ,15 g/d alcohol group because of sparse stratum-specific case numbers.
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The Japan Public Health Center-based Study Cohort I and the Beta-Carotene and Retinol Efficacy Trial were excluded from the 15 g/d alcohol group because of sparse stratum-specific case numbers. In addition, for the analysis of ER2 breast cancer, the CLUE II: Campaign Against Cancer and Heart Disease, the Swedish Mammography Cohort, and the Women's Lifestyle and Health Study were excluded from the 15 g/d alcohol group because of sparse stratum-specific case numbers.
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biological effects of intake. Year-to-year variation in diet likely exists. The use of a single questionnaire will therefore also contribute to error in the estimation of longer term intake, which is likely to be important in the etiology of breast cancer. In addition, correction for misclassification in intake estimates resulted in stronger inverse associations between intakes of a-carotene, b-carotene, b-cryptoxanthin, and lutein/zeaxanthin and ER2 breast cancer risk, which suggests that the true associations between dietary factors and disease risk might be underestimated substantially by using FFQs. In addition, because we measured carotenoid intake only at baseline, we cannot evaluate the possible effect of intakes during other life periods (eg, childhood) or changes in carotenoid intakes during follow-up. An additional limitation of the study included the relatively high correlations between individual carotenoids, which made assessment of independent associations difficult. However, the observed results were essentially unchanged when we mutually adjusted intakes of the 5 carotenoids. Also, the observed associations with dietary carotenoids may have been due to their correlation with other bioactive constituents of fruit or vegetables. When we further adjusted for dietary folate and vitamin C intakes, the results were similar. However, the associations with specific carotenoids should be interpreted with caution because they may still be due to other unmeasured or unadjusted constituents of fruit and vegetables. Although an influence of the missing ER and PR status on the observed results is possible, no substantial differences were found between cases with and those without receptor status according to age, BMI, alcohol consumption, and some other reproductive factors. Our study populations are mainly of European origin, which limited our ability to examine the potential effect of carotenoid intakes on breast cancer risk in other ethnic groups, such as African American and Asian populations.
In summary, although intakes of specific carotenoids, except for b-cryptoxanthin, were not significantly associated with overall risk of breast cancer, a-carotene, b-carotene, and lutein/ zeaxanthin intakes were associated with a modestly lower risk of ER2, but not ER+, breast cancer. However, these results need to be interpreted with caution because it is unclear whether the observed associations are due to specific carotenoids or to other constituents of the same foods although when we adjusted for dietary vitamin C and folate intakes, other nutrients present in fruit and vegetables, the associations remained. Additional research is needed to identify the potential mechanisms that may account for the observed findings. Additional studies of plasma carotenoids and genetic variants in the carotenoid-metabolizing pathway in relation to ER2 breast cancer may be useful in elucidating further the role of carotenoid intakes on the risk of ER2 breast cancer.
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